Cargando…
GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014
G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today. The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these. Thus, there is huge potential in terms of the number of targets for new...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495723/ https://www.ncbi.nlm.nih.gov/pubmed/25772061 http://dx.doi.org/10.1007/s00210-015-1111-8 |
_version_ | 1782380299088297984 |
---|---|
author | Heifetz, Alexander Schertler, Gebhard F. X. Seifert, Roland Tate, Christopher G. Sexton, Patrick M. Gurevich, Vsevolod V. Fourmy, Daniel Cherezov, Vadim Marshall, Fiona H. Storer, R. Ian Moraes, Isabel Tikhonova, Irina G. Tautermann, Christofer S. Hunt, Peter Ceska, Tom Hodgson, Simon Bodkin, Mike J. Singh, Shweta Law, Richard J. Biggin, Philip C. |
author_facet | Heifetz, Alexander Schertler, Gebhard F. X. Seifert, Roland Tate, Christopher G. Sexton, Patrick M. Gurevich, Vsevolod V. Fourmy, Daniel Cherezov, Vadim Marshall, Fiona H. Storer, R. Ian Moraes, Isabel Tikhonova, Irina G. Tautermann, Christofer S. Hunt, Peter Ceska, Tom Hodgson, Simon Bodkin, Mike J. Singh, Shweta Law, Richard J. Biggin, Philip C. |
author_sort | Heifetz, Alexander |
collection | PubMed |
description | G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today. The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these. Thus, there is huge potential in terms of the number of targets for new therapies to be designed. Several breakthroughs in GPCRs biased pharmacology, structural biology, modelling and scoring have resulted in a resurgence of interest in GPCRs as drug targets. Therefore, an international conference, sponsored by the Royal Society, with world-renowned researchers from industry and academia was recently held to discuss recent progress and highlight key areas of future research needed to accelerate GPCR drug discovery. Several key points emerged. Firstly, structures for all three major classes of GPCRs have now been solved and there is increasing coverage across the GPCR phylogenetic tree. This is likely to be substantially enhanced with data from x-ray free electron sources as they move beyond proof of concept. Secondly, the concept of biased signalling or functional selectivity is likely to be prevalent in many GPCRs, and this presents exciting new opportunities for selectivity and the control of side effects, especially when combined with increasing data regarding allosteric modulation. Thirdly, there will almost certainly be some GPCRs that will remain difficult targets because they exhibit complex ligand dependencies and have many metastable states rendering them difficult to resolve by crystallographic methods. Subtle effects within the packing of the transmembrane helices are likely to mask and contribute to this aspect, which may play a role in species dependent behaviour. This is particularly important because it has ramifications for how we interpret pre-clinical data. In summary, collaborative efforts between industry and academia have delivered significant progress in terms of structure and understanding of GPCRs and will be essential for resolving problems associated with the more difficult targets in the future. |
format | Online Article Text |
id | pubmed-4495723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-44957232015-07-09 GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 Heifetz, Alexander Schertler, Gebhard F. X. Seifert, Roland Tate, Christopher G. Sexton, Patrick M. Gurevich, Vsevolod V. Fourmy, Daniel Cherezov, Vadim Marshall, Fiona H. Storer, R. Ian Moraes, Isabel Tikhonova, Irina G. Tautermann, Christofer S. Hunt, Peter Ceska, Tom Hodgson, Simon Bodkin, Mike J. Singh, Shweta Law, Richard J. Biggin, Philip C. Naunyn Schmiedebergs Arch Pharmacol Meeting Report G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today. The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these. Thus, there is huge potential in terms of the number of targets for new therapies to be designed. Several breakthroughs in GPCRs biased pharmacology, structural biology, modelling and scoring have resulted in a resurgence of interest in GPCRs as drug targets. Therefore, an international conference, sponsored by the Royal Society, with world-renowned researchers from industry and academia was recently held to discuss recent progress and highlight key areas of future research needed to accelerate GPCR drug discovery. Several key points emerged. Firstly, structures for all three major classes of GPCRs have now been solved and there is increasing coverage across the GPCR phylogenetic tree. This is likely to be substantially enhanced with data from x-ray free electron sources as they move beyond proof of concept. Secondly, the concept of biased signalling or functional selectivity is likely to be prevalent in many GPCRs, and this presents exciting new opportunities for selectivity and the control of side effects, especially when combined with increasing data regarding allosteric modulation. Thirdly, there will almost certainly be some GPCRs that will remain difficult targets because they exhibit complex ligand dependencies and have many metastable states rendering them difficult to resolve by crystallographic methods. Subtle effects within the packing of the transmembrane helices are likely to mask and contribute to this aspect, which may play a role in species dependent behaviour. This is particularly important because it has ramifications for how we interpret pre-clinical data. In summary, collaborative efforts between industry and academia have delivered significant progress in terms of structure and understanding of GPCRs and will be essential for resolving problems associated with the more difficult targets in the future. Springer Berlin Heidelberg 2015-03-14 2015 /pmc/articles/PMC4495723/ /pubmed/25772061 http://dx.doi.org/10.1007/s00210-015-1111-8 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Meeting Report Heifetz, Alexander Schertler, Gebhard F. X. Seifert, Roland Tate, Christopher G. Sexton, Patrick M. Gurevich, Vsevolod V. Fourmy, Daniel Cherezov, Vadim Marshall, Fiona H. Storer, R. Ian Moraes, Isabel Tikhonova, Irina G. Tautermann, Christofer S. Hunt, Peter Ceska, Tom Hodgson, Simon Bodkin, Mike J. Singh, Shweta Law, Richard J. Biggin, Philip C. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 |
title | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 |
title_full | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 |
title_fullStr | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 |
title_full_unstemmed | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 |
title_short | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 |
title_sort | gpcr structure, function, drug discovery and crystallography: report from academia-industry international conference (uk royal society) chicheley hall, 1–2 september 2014 |
topic | Meeting Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495723/ https://www.ncbi.nlm.nih.gov/pubmed/25772061 http://dx.doi.org/10.1007/s00210-015-1111-8 |
work_keys_str_mv | AT heifetzalexander gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT schertlergebhardfx gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT seifertroland gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT tatechristopherg gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT sextonpatrickm gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT gurevichvsevolodv gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT fourmydaniel gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT cherezovvadim gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT marshallfionah gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT storerrian gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT moraesisabel gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT tikhonovairinag gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT tautermannchristofers gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT huntpeter gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT ceskatom gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT hodgsonsimon gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT bodkinmikej gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT singhshweta gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT lawrichardj gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 AT bigginphilipc gpcrstructurefunctiondrugdiscoveryandcrystallographyreportfromacademiaindustryinternationalconferenceukroyalsocietychicheleyhall12september2014 |